UniQure (QURE) said Monday that it has completed enrollment in the first cohort of patients of the phase 1/2a trial of its gene therapy candidate, AMT-191, for the treatment of Fabry disease.
The firm also said the Independent Data Monitoring Committee recommended proceeding with enrollment in the second cohort after it found no significant safety concerns following a safety data review from the first cohort's initial two patients.
The company said it expects to initiate enrollment of second dose cohort in the first quarter of 2025.
Price: 15.47, Change: -0.27, Percent Change: -1.72
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。